NEW YORK, Oct. 26, 2017 (GLOBE NEWSWIRE) — TPP Healthcare, a strategic advisory firm specializing in cross-border transactions between Western and Chinese healthcare companies, announces another successful Chinese expansion – partnering Legacy Healthcare, a Swiss-based R&D firm, with Maxhealth, a Chinese commercial healthcare firm.
Legacy Healthcare is a biopharma player developing innovative drugs in oncology supportive care and dermatology. The company has one product on the market, two in clinical development (Phase II and Phase III), and one in preclinical stage. Its anti-hair loss patented cosmetic product (CG 210) was launched in Europe by Sanofi, in South East Asia by Abbott and more recently in the US, Latin America, Russia, India and other markets by Galderma (Nestlé Skin Health).
Through TPP, Legacy Healthcare is now partnered with Maxhealth to commercialize CG 210 in Mainland China and Macao, a key market where CG 210 was not previously available. Beyond the distribution agreement, Maxhealth will take an equity position in Legacy Healthcare.
TPP Healthcare advised Legacy Healthcare in a four-tier process: Research (identifying and filtering), Outreach, Deal Structure, and Negotiation. The TPP team assisted Legacy Healthcare to interface with numerous Chinese firms – arranging confidentiality agreements, exchanging diligence documentation, and negotiating term sheets.
“Adverse drug reactions are now among the top five leading causes of death, with costs more than $170bn per year. At Legacy Healthcare, our objective is to develop treatments without the current burden of side-effects, especially for chronic conditions. Botanical drugs, an emerging class of drugs, might be the answer. Derived from botanical extracts, provided they are known to be safe for human use, botanical drugs have the potential for faster development, lower R&D investment, and are more appropriate for longer treatment periods since they carry less-to-no side effects compared to synthetic drug treatments. Additionally, our botanical treatments provide the same benefits as synthetic drugs – such as patent protection and same approval type,” states Saad Harti, CEO and Founder of Legacy Healthcare.
Harti continues, “For China, it was important for us to partner with a local, deep rooted company. TPP was instrumental in identifying the right partner in China. We could not have had a more professional team on our side and look forward to continuing our collaboration in the future.”
With an experienced team of well-connected industry veterans from all over the world, and the largest network in China’s healthcare industry, TPP Healthcare is the market expert with a top-notch network to execute and support cross-border transactions involving pharmaceuticals, medical devices, and diagnostics.
“Our goal is to introduce forward-thinking Chinese companies with the opportunity to invest in innovative healthcare companies and license their groundbreaking products and technologies in the Chinese market. China is the second largest pharma market in the world and due to its expanding aging population, its potential for growth is ensured. Chinese investors are looking for good investment opportunities abroad – now,” states Tony Chu, Managing Partner at TPP Healthcare. “At TPP, we take pride in knowing that our experience and in-depth understanding of China’s market helps our clients successfully secure fruitful partners.”
To learn more about Legacy Healthcare and TPP’s cross-border healthcare innovation and expansion, please contact Derrick Li, Partner of TPP Healthcare (derrick@thepharmapartners.com).
About TPP Healthcare
The Pharma Partners (TPP) Healthcare is a global advisory firm that functions to capture the macroeconomic shift of China’s market interest in healthcare innovation. Specializing in cross-border deal flow, TPP Healthcare is comprised of well-connected industry veterans from all over the world – and the largest network in China’s healthcare industry. By serving as a bridge between healthcare companies and investors from China and groundbreaking and innovative products and technologies from North America and Europe, TPP has become the market expert with a top-notch network to execute and support cross-border transactions involving pharmaceuticals/therapeutics, medical devices and diagnostics.
About Legacy Healthcare
Legacy Healthcare is a biopharma company focused on the development of innovative patentable botanical drugs in oncology supportive care and dermatology. Legacy Healthcare’s core activities consist of Research & Development, Manufacturing (through Contract Manufacturing Organizations), Licensing and Guidance on market positioning. Legacy Healthcare is a privately held company registered and based in Lausanne, Switzerland. For more information, please visit: http://www.legacyhealthcare.ch
About Maxhealth
Maxhealth Medicine Group Co., LTD. is a professional Chinese medical product contract sales organization. The company itself is located in eastern China. Our company is specialized in providing product registration, market access, academic promotion, clinical education and marketing services for the world’s leading drugs and medical equipment manufacturers. The aim of our company is to provide and assist Chinese clinicians with the most advanced medical technologies and will continue to expand with a focus on products that would make differences to patients’ lives.
TPP HEALTHCARE MEDIA CONTACT:
Trisha Salerno
Event Director – TPP Healthcare
750 Third Avenue, 9th Floor
New York, NY 10017
Mobile: (516) 385-0315
E-Mail: trishasalerno@tpphealthcare.com
